PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
Diagnostic Imaging
DRUG: BAY86-9596|DRUG: BAY86-9596|DRUG: BAY86-9596|DRUG: Fludeoxyglucose (18F)-IBA
Visual assessment of lesions (tumor detection rate of BAY 86-9596 compared to FDG), Day of study drug administration
Quantitative analysis of BAY 86-9596 uptake into lesions (Standardized Uptake Values = SUVs), Day of study drug administration|Vital signs (ECG, blood pressure, Heart rate, Body temperature), At least 2 times within 8 days after treatment|Serum chemistry, Clotting status, Hematology, At least 2 times within 8 days after treatment|Adverse Event collection, At least 2 times within 8 days after treatment
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation